Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 150, Issue 5, Pages 881-894Publisher
WILEY
DOI: 10.1002/ijc.33875
Keywords
apolipoprotein-A2; biomarker; IPMN; PDAC; serum
Categories
Funding
- Project for Cancer Research and Therapeutic Evolution (P-CREATE) from AMED [20cm0106403h0005]
- Ministry of Education, Culture, Sports, Science and Technology of Japan [19H03856]
- Grants-in-Aid for Scientific Research [19H03856] Funding Source: KAKEN
Ask authors/readers for more resources
This study found that serum apoA2-i has potential clinical value in risk stratification of IPMN and associated cancer. It showed higher accuracy and sensitivity in diagnosing IPMN-associated cancer compared to the routine biomarker CA 19-9. Further validation in larger and independent international cohort studies is needed for clinical application.
Intraductal papillary mucinous neoplasms (IPMNs) are premalignant lesions of pancreatic cancer. An accurate serum biomarker, which allows earlier identification of asymptomatic individuals with high-risk for developing cancer, is of urgent need. Apolipoprotein A2-isoforms (apoA2-i) have previously been identified as biomarkers in pancreatic cancer. This study investigates a potential clinical application of the serum apoA2-i for risk stratification of IPMN and associated cancer. The concentrations of apoA2-i were retrospectively determined in 523 patient sera specimen, composed of 305 IPMNs with preinvasive lesions with different grades of dysplasia and invasive cancer, 140 pancreatic ductal adenocarcinoma, 78 with other cystic lesions and healthy controls cohorts, using an apoA2-i enzyme-linked immunosorbent assay kit. The diagnostic performance of serum apoA2-i was assessed and compared to routine clinical marker CA 19-9. ApoA2-i levels were significantly reduced in all IPMN samples regardless of stage compared to healthy controls. Receiver operating characteristic curve analysis of IPMNs with high-grade dysplasia and IPMN with associated carcinoma revealed the area under curve (AUC) of 0.91 and >0.94, respectively. The respective sensitivities were 70% and 83% with a specificity of 95%, and significantly higher than the gold standard biomarker CA 19-9. AUC values of apoA2-i for detecting IPMN-associated carcinoma of colloid and ductal subtypes were 0.990 and 0.885, respectively. ApoA2-i has the potential to early detect the risk of malignancy of patients with IPMN. The serological apoA2-i test in combination with imaging modalities could help improve the diagnosis of IPMN malignancy. Further validation in larger and independent international cohort studies is needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available